ConductScience.org, home
Carotid Angioplasty and Stenting Versus Endarterectomy in Asymptomatic Subjects Who Are at Standard Risk for Carotid Endarterectomy With Significant Extracranial Carotid Stenotic Disease (ACT I)
API referenceFor AI assistants

Trial · NCT00106938

Outcomes33

Each outcome the trial posted results for, in ClinicalTrials.gov's words.

1 to 20 of 33

Download this page as JSON
TypeOutcomeTime framePopulationUnitsMeasured as
PRIMARYComposite of Death, Stroke (Ipsilateral or Contralateral; Major or Minor) and Myocardial Infarction (DSMI) Through 30 Days Post-procedure, Plus Ipsilateral Stroke 31 to 365 Days.0 to 365 dayspercentage of participantsNUMBER
SECONDARYAcute Device Success: Xact Carotid StentOn day 0 after index procedureDevice success is per device basis including the attempted devices only, including the attempted Carotid Artery Stenting (CAS) device only.percentage of devicesNUMBER
SECONDARYAcute Device Success: Embolic Protection Device SystemOn day 0 after index procedureDevice success is per device basis including the attempted devices only, including the attempted Carotid Artery Stenting (CAS) device only.Percentage of devicesMEAN
SECONDARYProcedural Success0 to 30 days post procedure
The analysis population is Procedure success is per subject basis including the attempted CAS (carotid artery stenting) procedure only. CEA group is not part of analysis population for procedure success.
percentage of participantsNUMBER
SECONDARYComposite Morbidity Measure0 to 30 Days Post-procedureIntent-to-Treat (ITT) populationparticipantsNUMBER
SECONDARYFreedom From Clinically Indicated Target Lesion Revascularization(CI-TLR)0 to 180 dayspercentage of partcipantsNUMBER
SECONDARYFreedom From Clinically Indicated Target Lesion Revascularization0 to 365 dayspercentage of partcipantsNUMBER
SECONDARYFreedom From Clinically Indicated Target Lesion Revascularization0 to 730 dayspercentage of partcipantsNUMBER
SECONDARYFreedom From Clinically Indicated Target Lesion Revascularization0 to 1095 dayspercentage of partcipantsNUMBER
SECONDARYFreedom From Clinically Indicated Target Lesion Revascularization0 to 1460 dayspercentage of partcipantsNUMBER
SECONDARYFreedom From Clinically Indicated Target Lesion Revascularization0 to 1825 dayspercentage of partcipantsNUMBER
SECONDARYFreedom From Ipsilateral Stroke31 to 365 dayspercentage of participantsNUMBER
SECONDARYFreedom From Ipsilateral Stroke31 to 730 dayspercentage of participantsNUMBER
SECONDARYFreedom From Ipsilateral Stroke31 to 1095 dayspercentage of participantsNUMBER
SECONDARYFreedom From Ipsilateral Stroke31 to 1460 dayspercentage of participantsNUMBER
SECONDARYFreedom From Ipsilateral Stroke31 to 1825 dayspercentage of participantsNUMBER
SECONDARYFreedom From Mortality0 to 365 dayspercentage of participantsNUMBER
SECONDARYFreedom From Mortality0 to 730 dayspercentage of participantsNUMBER
SECONDARYFreedom From Mortality0 to 1095 dayspercentage of partcipantsNUMBER
SECONDARYFreedom From Mortality0 to 1460 dayspercentage of participantsNUMBER

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

Next page

Sources 3

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
  • NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated
  • NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this list from software.

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT00106938/outcomes

API referenceFor AI assistants